Orchard Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C5328)
◆英語タイトル:Orchard Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5328
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年9月
◆ページ数:44
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Orchard Therapeutics Ltd (Orchard) is an integrated commercial-stage biotechnology company that develops gene therapies for the treatment of serious and life-threatening orphan diseases. Its pipeline products include Strimvelis, an autologous ex vivo gammaretroviral gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID); OTL-103 for Wiskott-Aldrich syndrome (WAS); OTL-102 for X-linked chronic granulomatous disease (X-CGD); OTL-300 for transfusion-dependent beta-thalassemia; and OTL-200 for metachromatic leukodystrophy (MLD), among others. The company works in partnership with institutions that specialize in gene and cell therapy such as The University of Manchester, Boston Children’s Hospital, and The San Raffaele Telethon Institute for Gene Therapy. It has operations in US and the UK with offices in London, San Francisco and Boston. Orchard is headquartered in London, the UK.

Orchard Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12
Venture Financing 13
Orchard Therapeutics Raises USD150 Million in Series C Financing 13
Orchard Therapeutics Raises USD110 Million in Series B Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18
Partnerships 19
Orchard Therapeutics and MolMed Expand Collaboration Agreement 19
Orchard Therapeutics Enters into Agreement with Genethon 20
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21
Licensing Agreements 23
Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23
Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24
Orchard Therapeutics Ltd – Key Competitors 25
Orchard Therapeutics Ltd – Key Employees 26
Orchard Therapeutics Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Aug 28, 2018: Orchard Therapeutics expands leadership team with appointments of head of corporate communications and head of human resources 28
Aug 02, 2018: Orchard Therapeutics appoints Jon Ellis to Board of Directors 29
Jul 09, 2018: Orchard Therapeutics Names Joanne Beck As Board Director 30
Jun 29, 2018: Orchard Therapeutics Appoints Jim Geraghty as Chairman of its Board of Directors 31
Jun 07, 2018: Orchard Therapeutics Appoints Marc Dunoyer And Charlie Rowland As Board Directors 32
Mar 21, 2018: Orchard Therapeutics Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer and General Counsel 33
Feb 21, 2018: Orchard Therapeutics Appoints Dr. Harry Malech to Scientific Advisory Board 34
Jan 17, 2018: Orchard Therapeutics Appoints Frank Thomas as Chief Financial Officer and Chief Business Officer 35
Aug 10, 2017: Orchard Therapeutics appoints Mark Rothera as CEO 36
Government and Public Interest 37
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 37
Product News 39
10/23/2017: NICE approves gene therapy for rare ‘bubble baby syndrome’ 39
01/03/2018: NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’ 40
Product Approvals 41
May 03, 2018: Orchard Therapeutics OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy 41
Jul 24, 2017: Orchard Therapeutics announces that OTL-101 has Received a Rare Paediatric Disease Designation 42
Other Significant Developments 43
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12
Orchard Therapeutics Raises USD150 Million in Series C Financing 13
Orchard Therapeutics Raises USD110 Million in Series B Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18
Orchard Therapeutics and MolMed Expand Collaboration Agreement 19
Orchard Therapeutics Enters into Agreement with Genethon 20
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21
Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23
Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24
Orchard Therapeutics Ltd, Key Competitors 25
Orchard Therapeutics Ltd, Key Employees 26
Orchard Therapeutics Ltd, Subsidiaries 27

List of Figures
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Orchard Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報(Orchard Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆